Cancer

Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8⁺ T cells pretreated with a tool compound PPARα agonist decreased tumor growth and increased survival compared with adoptive transfer of control CD8⁺ T cells. Next steps could include testing T cells pretreated with PPARα agonists in other models of melanoma.

Abbott Laboratories and AbbVie Inc. market the PPARα agonist TriLipix fenofibric acid for dyslipidemia...